Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ONVO's Cash-to-Debt is ranked higher than
85% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NAS:ONVO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ONVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: N/A Max: 43000
Current: No Debt
0.1
43000
Equity-to-Asset 0.93
NAS:ONVO's Equity-to-Asset is ranked higher than
97% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:ONVO: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ONVO' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.39  Med: 0.93 Max: 0.96
Current: 0.93
-7.39
0.96
Interest Coverage No Debt
NAS:ONVO's Interest Coverage is ranked higher than
87% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. NAS:ONVO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ONVO' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 5
Altman Z-Score: 31.68
Beneish M-Score: 0.32
WACC vs ROIC
23.38%
-8735.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -915.73
NAS:ONVO's Operating Margin % is ranked lower than
91% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NAS:ONVO: -915.73 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ONVO' s Operating Margin % Range Over the Past 10 Years
Min: -5448.28  Med: -3955.84 Max: -778.53
Current: -915.73
-5448.28
-778.53
Net Margin % -911.80
NAS:ONVO's Net Margin % is ranked lower than
91% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. NAS:ONVO: -911.80 )
Ranked among companies with meaningful Net Margin % only.
NAS:ONVO' s Net Margin % Range Over the Past 10 Years
Min: -6820.05  Med: -4453.41 Max: -911.8
Current: -911.8
-6820.05
-911.8
ROE % -58.43
NAS:ONVO's ROE % is ranked lower than
75% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. NAS:ONVO: -58.43 )
Ranked among companies with meaningful ROE % only.
NAS:ONVO' s ROE % Range Over the Past 10 Years
Min: -90.29  Med: -69.58 Max: -58.43
Current: -58.43
-90.29
-58.43
ROA % -54.03
NAS:ONVO's ROA % is ranked lower than
73% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. NAS:ONVO: -54.03 )
Ranked among companies with meaningful ROA % only.
NAS:ONVO' s ROA % Range Over the Past 10 Years
Min: -3700  Med: -76.52 Max: -54.03
Current: -54.03
-3700
-54.03
ROC (Joel Greenblatt) % -989.76
NAS:ONVO's ROC (Joel Greenblatt) % is ranked lower than
84% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. NAS:ONVO: -989.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ONVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11894.96  Med: -2395.94 Max: -989.76
Current: -989.76
-11894.96
-989.76
GuruFocus has detected 2 Warning Signs with Organovo Holdings Inc $NAS:ONVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ONVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ONVO Guru Trades in Q1 2016

Paul Tudor Jones 29,872 sh (+0.31%)
» More
Q2 2016

ONVO Guru Trades in Q2 2016

Paul Tudor Jones 41,741 sh (+39.73%)
» More
Q3 2016

ONVO Guru Trades in Q3 2016

Jim Simons 82,063 sh (New)
Paul Tudor Jones 21,553 sh (-48.36%)
» More
Q4 2016

ONVO Guru Trades in Q4 2016

Paul Tudor Jones 31,035 sh (+43.99%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:NYSE:ENZ, NAS:OXFD, NAS:SRDX, NAS:RDNT, NAS:LNTH, OTCPK:CBIS, NAS:NVDQ, AMEX:SENS, NYSE:NVTA, NAS:FLGT, NAS:QTNT, NAS:FLDM, NAS:TTOO, OTCPK:CLIFF, NAS:TRIB, NAS:CTSO, AMEX:VNRX, NAS:NRCIA, NAS:AIQ, NAS:PMD » details
Traded in other countries:4OR.Germany, ONVO.Switzerland, 0R02.UK,
Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues.

Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.

Ratios

vs
industry
vs
history
PB Ratio 4.36
ONVO's PB Ratio is ranked lower than
58% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ONVO: 4.36 )
Ranked among companies with meaningful PB Ratio only.
ONVO' s PB Ratio Range Over the Past 10 Years
Min: 2.05  Med: 8.38 Max: 63.4
Current: 4.36
2.05
63.4
PS Ratio 70.73
ONVO's PS Ratio is ranked lower than
97% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. ONVO: 70.73 )
Ranked among companies with meaningful PS Ratio only.
ONVO' s PS Ratio Range Over the Past 10 Years
Min: 69.05  Med: 269.58 Max: 1744
Current: 70.73
69.05
1744
Current Ratio 16.20
ONVO's Current Ratio is ranked higher than
96% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ONVO: 16.20 )
Ranked among companies with meaningful Current Ratio only.
ONVO' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 13.23 Max: 34
Current: 16.2
0.04
34
Quick Ratio 16.13
ONVO's Quick Ratio is ranked higher than
97% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ONVO: 16.13 )
Ranked among companies with meaningful Quick Ratio only.
ONVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 13.21 Max: 34
Current: 16.13
0.04
34
Days Inventory 159.60
ONVO's Days Inventory is ranked lower than
75% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. ONVO: 159.60 )
Ranked among companies with meaningful Days Inventory only.
ONVO' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 159.6
Current: 159.6
0
159.6
Days Sales Outstanding 94.79
ONVO's Days Sales Outstanding is ranked lower than
73% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. ONVO: 94.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
ONVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.4  Med: 56.58 Max: 94.79
Current: 94.79
49.4
94.79
Days Payable 340.92
ONVO's Days Payable is ranked higher than
95% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. ONVO: 340.92 )
Ranked among companies with meaningful Days Payable only.
ONVO' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 340.92
Current: 340.92
0
340.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.10
ONVO's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. ONVO: -14.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ONVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.1  Med: -11.7 Max: -2.7
Current: -14.1
-14.1
-2.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.79
ONVO's Price-to-Net-Cash is ranked higher than
80% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.06 vs. ONVO: 4.79 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ONVO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.48  Med: 8.16 Max: 47.25
Current: 4.79
3.48
47.25
Price-to-Net-Current-Asset-Value 4.64
ONVO's Price-to-Net-Current-Asset-Value is ranked higher than
74% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. ONVO: 4.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ONVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.44  Med: 8.02 Max: 42
Current: 4.64
3.44
42
Price-to-Tangible-Book 4.37
ONVO's Price-to-Tangible-Book is ranked higher than
59% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. ONVO: 4.37 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ONVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 7.66 Max: 35.66
Current: 4.37
3.22
35.66
Price-to-Median-PS-Value 0.26
ONVO's Price-to-Median-PS-Value is ranked higher than
93% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. ONVO: 0.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ONVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1.12 Max: 6.19
Current: 0.26
0.26
6.19
Earnings Yield (Greenblatt) % -15.11
ONVO's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ONVO: -15.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ONVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.58  Med: 2.6 Max: 3.9
Current: -15.11
-15.58
3.9

More Statistics

Revenue (TTM) (Mil) $3.97
EPS (TTM) $ -0.37
Beta2.79
Short Percentage of Float14.32%
52-Week Range $2.00 - 4.99
Shares Outstanding (Mil)104.41
» More Articles for NAS:ONVO

Headlines

Articles On GuruFocus.com
Why 3D Printing and Biotech Will Be Good Bets in 2017 Feb 23 2017 
Investors Are 3-D Printing Their Gains Nov 21 2016 
2015 Must-Buys In Biotech Sector Feb 02 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 
This 3D Printing Company Is a Solid Long-Term Buy Jul 26 2014 
Why Organovo Is a Better Buy Than 3D Systems May 14 2014 
Dump 3D Systems and Buy Organovo May 09 2014 
Why Organovo Is The Only 3D Printing Company Worth Buying Apr 25 2014 

More From Other Websites
Organovo Publishes Data Describing Physiology of 3D Bioprinted Human Kidney Tissues for Drug... Feb 21 2017
ORGANOVO HOLDINGS, INC. Financials Feb 15 2017
Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q3, 2017 By the Numbers : February 15, 2017 Feb 15 2017
Edited Transcript of ONVO earnings conference call or presentation 9-Feb-17 10:00pm GMT Feb 10 2017
Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News Feb 10 2017
Organovo reports 3Q loss Feb 09 2017
Organovo reports 3Q loss Feb 09 2017
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 09 2017
Organovo Announces Fiscal Third-Quarter 2017 Results; Company Updates Full-Year Fiscal 2017 Total... Feb 09 2017
Q3 2017 Organovo Holdings Inc Earnings Release - Before Market Open Feb 09 2017
Coverage initiated on Organovo by Raymond James Jan 25 2017
Organovo Holdings, Inc. breached its 50 day moving average in a Bearish Manner : ONVO-US : January... Jan 24 2017
Organovo Collaborates With Professor Melissa Little for Kidney Tissue Research Jan 24 2017
Organovo Announces Release Date for Fiscal Third-Quarter 2017 Financial Results Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)